EGFR and cancer: Over recent decades, therapeutic strategies have evolved from traditional cytotoxic agents like platinum-based compounds and taxanes [2] to targeted therapies that inhibit molecular drivers (e.g., EGFR, HER2, BRAF) [3,4] and cancer vaccines [5].